The prevalence of multiple sclerosis (MS) and the age of affected patients are increasing
owing to increased longevity of the general population and the availability of effective …

Memantine for dementia - McShane, R - 2006 | Cochrane Library Skip to Content Cookies Our
site uses cookies to improve your experience. You can find out more about our use of cookies …

Cochrane Page 1 Cochrane Library Cochrane Database of Systematic Reviews Memantine
for dementia (Review) McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L …

Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disorder of the central
nervous system (CNS) and one of the leading causes of neurological deficits and disability …

Purpose To evaluate the effectiveness and safety of oral memantine as a potential
neuroprotective agent in open-angle glaucoma (OAG) at risk for progression. Design Two …

Management of symptoms in multiple sclerosis (MS) has received little attention compared
with disease-modifying treatments. However, the effect of these symptoms on quality of life …

We review current pharmacological treatments for peripheral and central vestibular
disorders, and ocular motor disorders that impair vision, especially pathological nystagmus …

As more investigations into factors affecting the quality of life of patients with multiple
sclerosis (MS) are undertaken, it is becoming increasingly apparent that certain …

Research advances support the idea that excessive activation of the glutamatergic pathway
plays an important part in the pathophysiology of multiple sclerosis. Beyond the well …

The previous understanding of multiple sclerosis was solely related to neuroinflammation
and its harmful effects; however, countless data indicate the importance of some …